University of Dundee researchers in areas as diverse as microbiology, engineering, drug discovery, and archive and record development are among those to benefit from more than £3.8million in grants being distributed by the Royal Society of Edinburgh.
Top researchers are to develop their ideas here in Scotland, thanks to grants totalling £3.87 million awarded by The Royal Society of Edinburgh (RSE). Innovative research is being supported through the RSE in partnership with key funders in the public and private sectors. Of the recipients three are Principal Investigators at the College of Life Sciences.
Dr Michelle Scott of the Division Biological Chemistry and Drug Discovery, received the RSE Personal Research Fellowships in the Biomedical Sciences for her work into the ‘characterisation of the nucleolar protein interaction network.
Dr. Scott said, “The aim of the research is to better understand the complex network of proteins that carry out the fundamental but sometimes poorly understood processes in the nucleolus of the cell.”
“This fellowship will allow me to perform an in depth analysis of the wealth of knowledge that has been generated here in Dundee as well as elsewhere, by researchers in the biological sciences studying the nucleolus. The integration of these diverse pieces of information using computer science concepts will gives us a much more complete picture of this important cellular compartment.”
Dr Arnaud Javelle of the Department of Molecular and Environmental Microbiology also received an RSE Personal Research Fellowship for his work on the ’characterization of the ubiquitous sulphate transporter from the SulP family’, while Dr Iva Navratilova received an RSE Enterprise Fellowship.
Dr. Navratilova is a recognized world expert in developing SPR screening methods, especially for membrane proteins, expertise which has considerable commercial potential in its own right.
Dr. Navratilova outlined the importance of her research to drug discovery and the resulting revenue: “Compounds with slow off-rate kinetics are correlated with improved chance of success in the clinic and thus there is a growing demand by drug designers for complete kinetic characterization for each compound. My group intends to build its own intellectual property in screening and lead discovery from its services revenue base and proposes to generate revenue by serving this market.”